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background: NT-proBNP has been reported as predictor of survival in severe aortic stenosis (AS). Aim of this study was to examine the change in 
NT-proBNP levels over time and its value as predictor of outcome after treatment with transfemoral aortic valve implantation (TAVI).
Methods: From May 2007 until June 2013, 142 consecutive patients with severe AS (mean age 83 years (63-95), 56 male, AVA 0.58cm² (0.3-
1.1) underwent TAVI in our department (23 CoreValve, 119 Edwards Sapien). Plasma NT-proBNP, left ventricular function (LVF), mitral regurgitation 
(MR), NYHA symptoms class, hemoglobin and creatinine were analysed at baseline, 30 days, 6 months and 1 year after TAVI, and paravalvular aortic 
regurgitation (AR) at 30 days and 6 months.
results: Median baseline NT-proBNP before TAVI was 1912 pg/ml (IQR 1040.5-4750pg/ml). At 30 days NT-proBNP showed a trend in reduction 
(1715 pg/ml IQR 858.3-3455pg/ml; p=0.072). A significant decrease at 6 months was observed (1214.5 pg/ml; IQR 631.9-2805.8pg/ml; 
p=0.0018) as well as one year after TAVI (1271.5pg/ml;IQR 653.8-2395pg/ml; p=0.007). Mean LV function at 30 days showed only minimal 
change, but after 6 months and at 1 year was significantly increased (p=0.006, respectively). There was a significant reduction of NYHA at 30 days 
(p=0.0001), at 6 months (p=0.0001) and 1 year (p=0.0001). NYHA class was significantly related to NT-proBNP. Analysis of MR showed a trend in 
reduction after 6 months (p=0.095), with significant reduction after 1 year (p=0.015). Hemoglobin and creatinine significantly improved 6 months 
after TAVI compared to baseline (p=0.0001 for both). Interestingly, paravalvular AR after TAVI decreased significantly between 30 days and 6 months 
after TAVI (p=0.001). Baseline NT-proBNP was significantly higher in 51 pts that died after median 210 days (IQR 66-741) compared to surviving 
patients (p=0.016).
conclusion: Release of pressure overload is reflected by a significant reduction of NT-proBNP accompanied by improval of NYHA stage. Higher BNP 
before TAVI is associated with lower survival. However, TAVI is a feasible option for elderly patients with high surgical risk and improves hemoglobin, 
renal function and degree of MR.
